Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
AB Sciex

Blood Test Helps Identify Depressed Patients

By Labmedica International staff writers
Posted on 14 Feb 2012
A blood test helps diagnose major depressive disorder (MDD) and could become a useful clinical tool.

The blood test, which analyzes levels of nine biomarkers, accurately distinguished patients diagnosed with depression from control participants. There were no significant false-positive results.

Developed by Ridge Diagnostics (Research Triangle Park, NC, USA), the test measures levels of biomarkers associated with factors such as inflammation, the development and maintenance of neurons, and the interaction between brain structures involved with stress response and other key functions.

The measurements are combined using a specific formula to produce a figure called the MDDScore, a number from 1 to 100 indicating the percentage likelihood that the individual has major depression. In clinical use the MDDScore would range from 1 to 10.

The initial study included 36 adults who had been diagnosed with major depression at the Massachusetts General Hospital (MGH; Boston, MA, USA), Vanderbilt University or Cambridge Health Alliance (Cambridge, MA, USA) and 43 control participants from St. Elizabeth's Hospital (Brighton, MA, USA).

MDDScores for 33 of the 36 patients indicated the presence of depression, while only 8 of the 43 controls had a positive test result. The average score for patients was 85, while the average for controls was 33. A second replication phase study included 34 patients from the MGH and Vanderbilt, 31 of whom had a positive MDDScore result. Combining both groups indicated that the test could accurately diagnose major depression with a sensitivity of about 90 % and a specificity of 80 %.

A report of the studies was published in the December 2011 journal Molecular Psychiatry.

"Traditionally, diagnosis of major depression and other mental disorders has been made based on patients' reported symptoms, but the accuracy of that process varies a great deal, often depending on the experience and resources of the clinician conducting the assessment," said George Papakostas, MD, of the MGH department of Psychiatry, lead and corresponding author of the report. "Adding an objective biological test could improve diagnostic accuracy and may also help us track individual patients' response to treatment."

Antidepressant drugs are the most frequently prescribed medication in the United States today where depression strikes over 19 million adults each year–more than coronary artery disease, cancer, or AIDS. Objective biological test information about depression may aid physicians in the differential diagnosis of MDD, the selection of proper treatment, and effective management of their patients.

Related Links:

Ridge Diagnostics
Massachusetts General Hospital
Cambridge Health Alliance



DRG International
77 ELEKTRONIKA
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel

Heart Attack Biomarkers Accurate in Chronic Kidney Disease Patients

Two blood peptide biomarkers that are indicators of heart attack in the general population also provide critical information regarding heart status in chronic kidney disease patients. High-sensitivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict heart failure (HF) in the... Read more

Industry News

view channel

GlaxoSmithKline Boosts Global Cancer Testing With GE Healthcare Deal

The new agreement between GE Healthcare-subsidiary Clarient (Aliso Viejo, CA, USA) and GlaxoSmithKline (GSK; Brentford, UK) will create a force in cancer testing, according to Kalorama Information (New York City, NY, USA). The two entities will form a multipurpose, data analytics- and companion diagnostics (CDx)-driven... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.